What is HC Wainwright’s Estimate for ACRV Q1 Earnings?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Analysts at HC Wainwright issued their Q1 2025 EPS estimates for Acrivon Therapeutics in a research note issued to investors on Wednesday, March 26th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnings per share of ($0.63) for the quarter. HC Wainwright currently has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Acrivon Therapeutics’ Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.30) EPS, FY2026 earnings at ($2.77) EPS, FY2027 earnings at ($2.31) EPS and FY2028 earnings at ($1.96) EPS.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its earnings results on Thursday, March 27th. The company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.06.

A number of other brokerages have also commented on ACRV. KeyCorp assumed coverage on shares of Acrivon Therapeutics in a research note on Friday, January 31st. They issued an “overweight” rating for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Acrivon Therapeutics in a research report on Wednesday. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, Acrivon Therapeutics has an average rating of “Buy” and a consensus target price of $23.17.

Acrivon Therapeutics Stock Performance

NASDAQ ACRV opened at $2.24 on Friday. The company has a market capitalization of $69.74 million, a price-to-earnings ratio of -0.83 and a beta of 0.85. The stock has a 50-day moving average of $5.35 and a 200 day moving average of $6.53. Acrivon Therapeutics has a one year low of $2.14 and a one year high of $11.90.

Institutional Trading of Acrivon Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. bought a new stake in shares of Acrivon Therapeutics during the 4th quarter valued at $40,000. Wealthedge Investment Advisors LLC purchased a new position in Acrivon Therapeutics during the fourth quarter valued at $65,000. Corton Capital Inc. bought a new stake in Acrivon Therapeutics during the fourth quarter valued at about $73,000. American Century Companies Inc. increased its position in Acrivon Therapeutics by 14.2% in the fourth quarter. American Century Companies Inc. now owns 17,588 shares of the company’s stock worth $106,000 after buying an additional 2,186 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Acrivon Therapeutics by 20.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 37,063 shares of the company’s stock worth $223,000 after buying an additional 6,239 shares during the period. 71.62% of the stock is owned by hedge funds and other institutional investors.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.